BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

An Open, Randomised Clinical Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Efficacy, Safety and Pharmacokinetics of Repeated Three-week Courses of a Single Dose i.v. BI 2536 on Day 1 in Comparison to Single Doses i.v. BI 2536 on Days 1, 2 and 3 in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML. Different schedules will be compared to identify the better dosing schedule for the further development programme of BI 2536. Dose escalation starting with the maximum tolerated dose previously determined in patients with advanced solid cancers will be performed to determine the maximum tolerated dose for AML patients.

Study Overview

• Status: Completed
• Conditions: Leukemia, Myeloid, Acute
• Intervention / Treatment: Drug: BI 2536

• Study Type: Interventional
• Enrollment (Actual): 71
• Phase: Phase 2

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria
    • 1216.20.43001 Boehringer Ingelheim Investigational Site
  • Wien, Austria
    • 1216.20.43002 Boehringer Ingelheim Investigational Site
• Germany
  • Bonn, Germany
    • 1216.20.49006 Boehringer Ingelheim Investigational Site
  • Frankfurt, Germany
    • 1216.20.49002 Boehringer Ingelheim Investigational Site
  • Freiburg, Germany
    • 1216.20.49003 Boehringer Ingelheim Investigational Site
  • Hannover-Heideviertel, Germany
    • 1216.20.49004 Boehringer Ingelheim Investigational Site
  • Heidelberg, Germany
    • 1216.20.49007 Boehringer Ingelheim Investigational Site
  • Münster, Germany
    • 1216.20.49005 Boehringer Ingelheim Investigational Site
  • Ulm, Germany
    • 1216.20.49001 Boehringer Ingelheim Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female patients older than 60 years of age
• Patient with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy
• Leukocyte count <= 25,000 /mcl (25 x 10e9/Liter)
• Patient not eligible for intensive treatment options
• Life expectancy >= 2 months
• Eastern co-operative oncology group performance score of 2 or less
• Signed written informed consent consistent with international conference on harmonisation - good clinical practice (ICH-GCP) and local legislation

Exclusion Criteria:

• Patient with acute promyelocytic leukaemia (APL, AML of the French-American-British (FAB) classification subtype M3)
• Hypersensitivity to the trial drug or the excipients
• Secondary malignancy requiring therapy
• Known central nervous system involvement
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal, or AST or ALT greater than 5 times the upper limit of normal in case of known liver involvement
• Bilirubin greater than 1.5 mg/dl (> 26 mcmol/l, SI unit equivalent)
• Serum creatinine greater than 2.0 mg/dl
• Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia
• Psychiatric illness or social situation that would limit compliance with trial requirements
• Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
• Chemotherapy (except hydroxyurea) or immunotherapy or treatment with any other investigational drug within the past four weeks prior to treatment with the trial drug
• Persistence of toxicities of prior anti-leukaemia therapies which are deemed to be clinically relevant
• Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)
• Patient unable to comply with the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Interventional Model: Parallel Assignment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Maximum tolerated dose Best objective response	3 weeks, throughout the study period

Secondary Outcome Measures

Outcome Measure	Time Frame
Event free survival, Overall survival, Remission duration, BI 2536 plasma concentrations, Incidence and intensity of adverse events graded according to CTCAE, PD, Incidence of DLT	throughout the study period

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Study record dates

Study Major Dates

• Study Start: October 1, 2006
• Primary Completion (Actual): October 1, 2009

Study Registration Dates

• First Submitted: June 18, 2008
• First Submitted That Met QC Criteria: June 18, 2008
• First Posted (Estimate): June 19, 2008

Study Record Updates

• Last Update Posted (Estimate): May 16, 2014
• Last Update Submitted That Met QC Criteria: April 30, 2014
• Last Verified: October 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute
• Other Study ID Numbers: 1216.20; EudraCT No:2006-000613-38